CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 420 enrolled
Drug / intervention
LY2944876 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02119819
NCT02119819Phase 2Completed
CompareCT.gov

Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients With Type 2 Diabetes

OPKO Health, Inc.·interventional·Posted Apr 22, 2014·Updated May 27, 2021

In Brief

A Phase 2 clinical trial evaluating LY2944876, Exenatide extended-release, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 420 participants across 51 sites in 6 countries.

Detailed Summary

The main purpose of this study is to compare the safety and effectiveness of the study drug known as LY2944876 to exenatide extended-release and placebo in participants with type 2 diabetes mellitus. All drugs will be given by an injection under the skin. Participants remain on stable doses of metformin, as prescribed by their personal investigator if they were on metformin at study entry. Participants' involvement in the study is expected to last about 30 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGreece, Mexico, Poland, Puerto Rico, Romania, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 22, 2014
Enrollment StartApr 1, 2014
Primary CompletionAug 1, 2015
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.2 years ago

Interventions

LY2944876drug

Administered SC

Exenatide extended-releasedrug

Administered SC

Placebodrug

Administered SC

Metformindrug

Oral